Abacus FCF Advisors LLC Buys 2,828 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Abacus FCF Advisors LLC increased its stake in Gilead Sciences by 1.7%, now holding 165,014 shares worth approximately $18.3 million, making it the firm's 10th largest holding.
• CEO Daniel Patrick O'day sold 10,000 shares of Gilead stock for about $1.14 million, reducing his ownership by 1.65%.
• Gilead Sciences recently announced a quarterly dividend of $0.79 per share, with an upcoming payout date of September 29th, reflecting an annual yield of 2.8%.

Abacus FCF Advisors LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 165,014 shares of the biopharmaceutical company's stock after purchasing an additional 2,828 shares during the quarter. Gilead Sciences comprises about 2.6% of Abacus FCF Advisors LLC's investment portfolio, making the stock its 10th biggest position. Abacus FCF Advisors LLC's holdings in Gilead Sciences were worth $18,295,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the 1st quarter valued at about $25,000. Activest Wealth Management grew its holdings in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences in the first quarter valued at approximately $29,000. Colonial Trust Advisors boosted its holdings in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the period. Finally, Core Alternative Capital boosted its holdings in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 1.9%

Shares of NASDAQ:GILD traded up $2.13 during trading on Tuesday, reaching $114.62. 3,483,414 shares of the company traded hands, compared to its average volume of 8,064,619. The firm has a market capitalization of $142.23 billion, a price-to-earnings ratio of 22.84, a P/E/G ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $81.83 and a 52-week high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The business's fifty day moving average is $114.11 and its 200-day moving average is $109.95.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GILD shares. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a report on Friday, July 25th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Finally, Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $117.17.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer owned 159,555 shares of the company's stock, valued at $18,120,661.35. This represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares of the company's stock, valued at $12,855,329.01. This represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,390,030 in the last quarter. 0.27% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.